(Q57515334)

English

An update to “The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe”

article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

0 references

An update to “The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe” (English)

0 references

cost-effectiveness analysis

1 reference

based on heuristic

inferred from title

Marie-Josée J Mangen

object named as

Marie-Josée J. Mangen

2

0 references

Philippe Beutels

object named as

Philippe Beutels

8

0 references

1

object named as

Mark Jit

0 references

7

object named as

W. John Edmunds

0 references

Yazdan Yazdanpanah

4

object named as

Yazdan Yazdanpanah

0 references

author name string

Hugues Melliez

3

0 references

Joke Bilcke

5

0 references

Heini Salo

6

0 references

language of work or name

0 references

publication date

November 2010

0 references

0 references

28

0 references

47

0 references

7457-7459

0 references

The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.060

7 January 2021

RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.060

7 January 2021

Is it cost-effective to introduce rotavirus vaccination in the Dutch national immunization program?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.060

7 January 2021

Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.060

7 January 2021

Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.060

7 January 2021

Cost-effectiveness of infant vaccination with RIX4414 (Rotarix) in the UK.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.060

7 January 2021

Cost-effectiveness analysis of vaccination against rotavirus with RIX4414 in France

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.060

7 January 2021

The cost-utility of rotavirus vaccination with Rotarix (RIX4414) in the Netherlands

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.060

7 January 2021

Reviewing the cost effectiveness of rotavirus vaccination: the importance of uncertainty in the choice of data sources

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.060

7 January 2021

Economic impact of healthcare-associated rotavirus infection in a paediatric hospital

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.060

7 January 2021

Costs of community-acquired pediatric rotavirus gastroenteritis in 7 European countries: the REVEAL Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.060

7 January 2021

Identifiers

10.1016/J.VACCINE.2010.08.060

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57515334&oldid=2032370166"